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BACKGROUND: The effect of care setting on value of colon cancer care is unknown. METHODS: A Surveillance, Epidemiology, and
End Results (SEER)-Medicare cohort study of 6544 patients aged 66 years with stage IV colon cancer (based on the American Joint
Committee on Cancer staging system) who were diagnosed between 1996 and 2005 was performed. All patients were followed
through December 31, 2007. Using outpatient and carrier claims, patients were assigned to a treating hospital based on the hospital
affiliation of the primary oncologist. Hospitals were classified academic or nonacademic using the SEER-Medicare National Cancer
Institute Hospital File. RESULTS: Of the 6544 patients, 1605 (25%) received care from providers affiliated with academic medical cen-
ters. The unadjusted median cancer-specific survival was 16.0 months at academic medical centers versus 13.9 months at nonaca-
demic medical centers (P<.001). After adjustment, treatment at academic hospitals remained significantly associated with a reduced
risk of death from cancer (hazard ratio, 0.87; 95% confidence interval [95% CI], 0.82-0.93 [P<.001]). Adjusted mean 12-month Medi-
care spending was $8571 higher at academic medical centers (95% CI, $2340-$14,802; P5.007). The adjusted median cost was $1559
higher at academic medical centers; this difference was not found to be statistically significant (95% CI, -$5239 to $2122; P5.41). A
small percentage of patients who received very expensive care skewed the difference in mean cost; the only statistically significant
difference in adjusted costs in quantile regressions was at the 99.9th percentile of costs (P<.001). CONCLUSIONS: Among Medicare
beneficiaries with stage IV colon cancer, treatment by a provider affiliated with an academic medical center was associated with a
2 month improvement in overall survival. Except for patients in the 99.9th percentile of the cost distribution, costs at academic medi-
cal centers were not found to be significantly different from those at nonacademic medical centers. Cancer 2014;120:3237-44. VC 2014
American Cancer Society.
KEYWORDS: colon cancer, academic medical centers, cost analysis, health policy, survival analysis, incremental cost-effectiveness
ratio.
INTRODUCTION
Nearly 20,000 individuals were expected to be diagnosed with metastatic colorectal cancer in the United States in 2013.1,2
As overall survival increases due to improved cancer treatment, costs of care rise exponentially. Colon cancer is not the only
cancer for which this holds true. More effective treatments are now available than ever before for patients with metastatic
solid tumors. Patients with stage IV breast, prostate, and lung cancer are living longer due to treatment advances.3-5 Although
the costs of cancer care in general have grown dramatically in the United States over the last decades, the costs of patients
with metastatic disease are particularly high.6 These patients tend to be older, have comorbid conditions, and receive costly
therapies such as surgical resection of metastases and molecularly targeted therapy.7-10 This growing financial burden has
adverse consequences for the US economy, governmental support of social programs, and individual patients.11
Given the cost and complexity of caring for older patients with metastatic colon cancer, the delivery of high-value
cancer care to this population is critically important. High-value care is defined as care that maximizes patient outcomes
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while containing the cumulative costs of care.12,13 It is
plausible that providers and the care setting substantially
influence the value of care delivered. For example, aca-
demic medical centers offer specialized providers and a
multidisciplinary approach to cancer care. However, the
role of academic medical centers in providing high-value
cancer care is uncertain. Care at an academic center has
been associated with better outcomes in some settings,
including surgery for colorectal cancer.14,15 However, aca-
demic medical centers have also been associated with
higher costs of care and little difference in quality meas-
ures in other settings.16-21 In the current study, we eval-
uated overall survival and costs of care for elderly patients
with stage IV colon cancer to determine whether hospital
academic status was associated with differences in the
value of the care delivered.
MATERIALS AND METHODS
Institutional Review
The current study was a retrospective cohort study of the
outcomes and costs of cancer care delivered to patients
with colon cancer diagnosed between January 1996 and
December 2005. This study was exempted from review by
the Institutional Review Board of the University of
Pennsylvania.
Study Population
We identified 83,731 patients who were diagnosed with
colon cancer between January 1, 1996 and December 31,
2005 from the Surveillance, Epidemiology, and End
Results (SEER)-Medicare files.
We excluded patients without a histologic finding of
adenocarcinoma (3168 patients), those in whom the diag-
nosis had been made at autopsy or on a death certificate (2
patients), or patients who were aged <66 years (to enable
inclusion of 1 year of claims for comorbidity assessment)
or >99 years at the time of diagnosis (11,278 patients).
Patients who did not have Medicare Part A or Medicare
Part B coverage (3754 patients) at any time during the
study period or patients who were enrolled in a health
maintenance organization in the 12 months before or the
12 months after diagnosis (13,097 patients) were
excluded because of incomplete claims data. Patients with
missing data regarding stage of disease or stage 0 disease
were excluded (908 patients). Of the remaining 51,524
patients, 40,862 were assigned to a treating hospital as
described below. Among these, 6549 patients had stage
IV cancer at diagnosis, based on the American Joint Com-
mittee on Cancer overall cancer stage provided in the
SEER files for each patient. Five patients with incomplete
or missing payment data were omitted, resulting in a final
cohort of 6544 patients who were followed through De-
cember 31, 2007.
Hospital Assignment
Because the majority of colon cancer care is delivered in
the outpatient setting, assigning a patient to a treating
hospital using inpatient claims can be challenging. We
assigned each patient in the current study cohort to a
treating hospital by applying a method developed by
Bynum et al22 in which patients are assigned to a hospital
based on their predominant ambulatory physicians’ hos-
pital affiliation. This method was previously validated in a
cohort of Medicare fee-for-service patients for whom both
generalists and medical specialists, including medical
oncologists, were identified as the predominant ambula-
tory physician.22 The patients’ primary medical oncolo-
gists were defined as the medical oncologist billing for the
greatest number of evaluation and management visits in
the 6 months before and 12 months after diagnosis. Medi-
cal oncologists were assigned to the one hospital in which
they provided the most inpatient care. Finally, patients
were assigned to a treating hospital based on the hospital
affiliation of their primary medical oncologist. Further
details regarding the hospital assignment method can be
found in the online supporting information.
Outcome Measures
We examined 2 distinct outcomes: overall survival and
cost of care. Overall survival was calculated as the number
of months from the date of the initial colon cancer diag-
nosis to the date of death or to December 31, 2007 if the
patient was still alive at the end of the follow-up period.
Cost of care was defined as the total payment made
by Medicare for each patient’s inpatient and outpatient
care, determined by summing payments obtained from
the Medicare Provider Analysis and Review file, the
National Claims History file, and the Outpatient Stand-
ard Analytic File. Costs were summed and analyzed over
the time interval extending to 12 months beyond the date
of the initial cancer diagnosis.
Predictor Variable
The primary predictor of interest was the academic status
of the treating hospital for each patient. Academic status
was obtained from the National Cancer Institute Hospital
File included in SEER-Medicare data. The National Can-
cer Institute obtains hospital information from the annual
Center for Medicare and Medicaid Services Health Care
Cost Report and Provider of Service survey. Hospitals
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classified in the Hospital File as having a major medical
school affiliation were considered academic hospitals in
the current analyses. All other hospitals were classified as
nonacademic hospitals.
Covariates
Before data analysis, we identified potential confounders
and effect modifiers of the association between hospital
academic status and the outcome variables. These
included patient age, race, sex, comorbidity score accord-
ing to Elixhauser et al23 excluding cancer-related diagno-
ses, and ZIP code-based socioeconomic status.
Statistical Analysis
To assess univariate associations between the type of hos-
pital (academic vs nonacademic) and clinical and demo-
graphic factors, we used chi-square tests for categorical
variables and Student t tests for continuous variables. We
constructed Kaplan-Meier curves to assess unadjusted
overall survival. We estimated a Cox proportional hazards
model to assess the association between hospital academic
status and overall survival while adjusting for important
patient characteristics. We modeled time to death from
any cause and time to colon cancer-related death.
To examine the association between hospital aca-
demic status and the mean cost of care while adjusting for
important patient characteristics, we estimated a general-
ized linear model with a log-link and a gamma family.
Standard errors were adjusted to account for clustering of
patients within hospitals. We also estimated quantile
regression models to examine associations between hospital
teaching status and cost of care at various quantiles (25th,
50th, 75th, 90th, 95th, 99th, 99.5th, and 99.9th) along the
cost distribution, while adjusting for important patient
characteristics. In all models, standard errors were adjusted
to account for clustering of patients within hospitals.
We assessed two-way interactions between hospital
academic status and patient age, race, and number of
comorbid conditions using likelihood ratio and Wald
tests to assess the joint significance of interaction terms;
no interactions were found to be statistically significant.
Statistical significance was set at a P value <.05. All
statistical analyses were performed using SAS statistical
software (version 9.1; SAS Institute Inc, Cary, NC) or
STATA software (version 12.1; STATA Corporation,
College Station, Tex).
RESULTS
Baseline Characteristics and Univariate Analysis
The final cohort consisted of 6544 patients with stage IV
colon cancer at the time of diagnosis. A total of 1605
patients (25%) received cancer care from providers affili-
ated with an academic hospital. Table 1 shows the base-
line characteristics of the cohort and univariate analyses of
associations between these characteristics and hospital aca-
demic status. Patients whose medical oncologists were
assigned to academic hospitals were more likely to be
black and in a higher income bracket (P<.001) than
patients whose medical oncologists were assigned to nona-
cademic hospitals. There were no significant differences
concerning age, sex, or comorbid conditions observed
with regard to hospital academic status.
Survival Analysis
Unadjusted Kaplan-Meier curves for all-cause and colon
cancer-specific mortality are shown in Figure 1. Univari-
ate analysis using log-rank testing indicated that academic
TABLE 1. Univariate Analysis of Patient






No. (%) 1605 4939
Vital status (as of 12/31/2007)
Alive 137 (9) 351 (7)
Dead 1468 (91) 4588 (93) .058
Age, y
65-69 321 (20) 982 (20)
70-74 444 (28) 1263 (26)
75-79 411 (26) 1309 (27)
80-84 278 (17) 874 (18)
85 151 (9) 511 (10) .469
Race
White 1262 (79) 4262 (86)
Black 212 (13) 396 (8)
Other 131 (8) 281 (6) <.001
Sex
Female 763 (48) 2310 (47)
Male 843 (52) 2633 (53) .588
No. of comorbid conditions
0 46 (3) 111 (2)
1 116 (7) 294 (6)
2 1443 (90) 4531 (92) .063
Median household income
0% to <25% 374 (23) 1363 (28)
25% to 50% 373 (23) 1287 (26)
50% to 75% 383 (24) 1256 (25)
75% to 100% 475 (30) 1033 (21) <.001
Y of diagnosis
1995 107 (7) 286 (6)
1996 111 (7) 274 (6)
1998 91 (6) 286 (6)
1999 109 (7) 252 (5)
2000 168 (10) 553 (11)
2001 176 (11) 609 (12)
2002 193 (12) 633 (13)
2003 195 (12) 572 (12)
2004 181 (11) 616 (13)
2005 146 (9) 551 (11) .003
Data shown are N (%). P values are derived from chi-square tests. Propor-
tions may not add to 100% because of rounding.
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status was significantly associated with improved survival;
the median survival (all-cause mortality) for patients with
stage IV colorectal cancer who were treated at academic
hospitals was 13.9 months compared with 11.9 months
for patients treated at nonacademic hospitals (P<.001).
The difference persisted for colon cancer-specific survival;
the median survival was 16.0 months for patients treated
at academic medical centers versus 13.9 months for
patients treated at nonacademic medical centers
(P<.001).
Hospital academic status was included in a Cox pro-
portional hazards model that adjusted for patient charac-
teristics. After adjustment, hospital academic status
remained significantly associated with improved survival
(all-cause mortality: hazard ratio [HR], 0.90; 95% confi-
dence interval [95% CI], 0.85-0.96 [P5 .001]; and colon
cancer-specific mortality: HR, 0.87; 95% CI, 0.82-0.93
[P<.001]). Table 2 shows results of the Cox proportional
hazards model.
Cost of Care
Twelve-month unadjusted and adjusted costs of care are
shown in Table 3. The unadjusted mean cost of care was
$6370 higher for patients treated at academic medical
centers (95% CI, $2123-$10,616; P5 .003), whereas the
unadjusted median cost of care was $490 higher for
patients treated at academic medical centers (95% CI, -
$3785 to $4765; P5 .822). Nominal differences in the
unadjusted median costs of care increased across the 25th,
50th, 75th, 90th, 95th, 99th, 99.5th and 99.9th percen-
tiles, with the greatest unadjusted difference in cost
($283,363) observed for those patients whose 12-month
costs fell within the 99.9th percentile. Only the unad-
justed differences in median cost at the 99.5th (P5 .009)
and 99.9th (P<.001) percentiles were found to be statisti-
cally significant.
Hospital academic status was included in a general-
ized linear model that adjusted for patient characteristics.
After adjustment, hospital academic status remained sig-
nificantly associated with a difference in the mean cost.
The adjusted mean cost of care was $8571 higher for
patients treated at academic medical centers (95% CI,
$2340-$14,802; P5 .007). The adjusted median cost of
care was $1559 higher for patients treated at academic
medical centers, and this was not statistically significant
(95% CI, -$5239 to $2122; P5 .410). Differences in
adjusted median costs increased across the 25th, 50th,
75th, 90th, 95th, 99th, 99.5th, and 99.9th percentiles,
with the greatest difference in adjusted median cost
($71,457) noted for those patients whose 12-month cost
of care fell within the 99.9th percentile. The only statisti-
cally significant adjusted difference in cost from the quan-
tile regressions was that observed at the 99.9th percentile
(P<.001).
DISCUSSION
The results of the current study indicate that for patients
with metastatic colon cancer at the time of diagnosis,
receiving colon cancer care from a provider affiliated with
an academic medical center was associated with a statisti-
cally significant increase in all-cause and colon cancer-
specific overall survival of approximately 2 months. Fur-
thermore, although the adjusted mean 12-month cost of
care was $8571 higher for patients treated at academic
medical centers and the difference was statistically signifi-
cant, the mean cost of care was skewed by a small percent-
age of patients who received very expensive care. In fact,
the adjusted median 12-month cost was a modest $1559
higher for patients treated at academic medical centers,
and this difference was not statistically significant.
Figure 1. Kaplan-Meier survival estimates of unadjusted over-
all survival are shown by hospital academic status. Dashed
lines represent academic medical centers and solid lines rep-
resent nonacademic medical centers.
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Moreover, our quantile regression indicated that the
adjusted difference in cost was significant only for those
patients whose costs fell within the 99.9th percentile.
To quantify the value of treatment at an academic
medical center, we estimated the incremental cost-
effectiveness ratio by dividing the incremental cost by the
incremental benefit. Using the higher estimate of incre-
mental cost based on the difference in means ($8571) and
the incremental benefit based on unadjusted median sur-
vival (2.1 months) implies that the “price” of an extra year
of survival from treatment at an academic medical center
is $48,977. The estimate drops to $8909 when measuring
the incremental cost at the median. This figure is only a
rough estimate and is not directly comparable to quality-
adjusted life year acceptability thresholds, such as the
common but arbitrary $50,000 per quality-adjusted life
year, because it does not account for quality of life. Never-
theless, these estimates compare favorably with a standard
TABLE 2. Effect of Hospital Academic Status on Adjusted Overall Survival: Cox Proportional Hazards
Modela
All-Cause Mortality Colon Cancer-Specific Mortality
Characteristic HR (95% CI) P HR (95% CI) P
Hospital academic status (vs nonacademic)
Academic 0.90 (0.85-0.96) .001 0.87 (0.82-0.93) <.001
Age (vs 65-69), y
70-74 1.08 (1.00-1.17) .041 1.07 (0.98-1.16) .12
75-79 1.20 (1.12-1.30) <.001 1.19 (1.10-1.30) <.001
80-84 1.41 (1.30-1.53) <.001 1.36 (1.24-1.50) <.001
85 1.81 (1.64-2.00) <.001 1.72 (1.55-1.92) <.001
Race (vs white)
Black 1.09 (0.87-1.23) .062 1.04 (0.94-1.15) .499
Other 0.93 (0.84-1.04) .208 0.91 (0.80-1.02) .105
Sex (vs female)
Male 1.04 (0.99-10.9) .133 1.09 (1.03-1.15) .004
No. of comorbid conditions (vs 0 conditions)
1 1.06 (0.87-1.23) .591 1.01 (0.81-1.25) .499
2 1.40 (1.18-1.67) <.001 1.34 (1.11-1.62) .002
Median household income (vs. 0% to <25%)
25% to 50% 0.95 (0.89-1.02) .163 0.92 (0.85-1.00) .052
50% to 75% 0.98 (0.92-1.06) .653 0.98 (0.91-1.06) .681
75% to 100% 0.94 (0.87-1.01) .103 0.94 (0.87-1.02) .144
Abbreviations: 95% CI, 95% confidence interval; HR, hazard ratio.
a Year of diagnosis was also included in the model; output not shown here.










Mean cost $56,797 $50,427 $6370 ($2123 to $10,616)b $8571 ($2340 to $14,802)c
Median cost $31,896 $31,406 $490 (-$3785 to $4765) $1559 (-$2133 to $25,251)
25th percentile $12,115 $11,769 $346 (-$1742 to $2434) $930 (21057 to $2917)
75th percentile $66,499 $63,546 $2953 (-$6,984 to $12,890) $1448 (-$4855 to $7751)
90th percentile $115,581 $111,456 $4125 (-$14,525 to $22,775) $7502 (-$4544 to $19,548)
95th percentile $188,545 $154,665 $33,880 (-$5129 to $72,890) $17,293 (-$12,121 to $46,707)
99th percentile $434,434 $324,740 $109,694 (-$61,050 to $280,438) $20,917 (-$35,686 to $77,521)
99.5th percentile $618,693 $465,032 $153,661 ($38,912 to $268,409)d $26,708 ($18,179 to $71,594)
99.9th percentile $1,005,610 $722,247 $283,363 ($156,534 to $410,191)e $71,457 ($48,330 to $94,584)f
Abbreviations: 95% CI, 95% confidence interval.
a The mean and median costs displayed in the first 2 columns are unadjusted costs. Unadjusted mean costs were obtained via a 2-sample Student t test, and
the adjusted difference in mean costs was obtained via a generalized linear model. Unadjusted and adjusted median and percentile-based costs were
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therapy for metastatic colorectal cancer, bevacizumab,
which improved the median survival by approximately
4.5 months at an annual cost of up to $100,000, suggest-
ing an incremental cost-effectiveness ratio of up to
$266,667 per year of life.24,25
The unadjusted, colon cancer-related, median over-
all survival of patients treated at academic (16.0 months)
and nonacademic (13.9 months) medical centers is lower
than the literature-based median overall survival of 24
months for patients with stage IV colorectal cancer.7 This
discrepancy is likely due to the finding that the current
study data were population-based and collected over the
course of 10 years, whereas survival rates currently
reported from studies reflect the increasing use of resec-
tion of liver metastases and combination chemotherapy
regimens.26,27 In fact, the hazard ratio for colon cancer-
specific death in the current study decreased steadily over
time (see online supporting information).
Although the absolute difference in survival was
modest, the relative effect of hospital academic status on
overall survival was substantial, with a 13% decreased risk
of colon cancer mortality and a 10% decreased risk of
overall mortality associated with treatment at an academic
medical center. There are several possible reasons for this
difference. First, the management of metastatic colon can-
cer has become increasingly complex. Providers associated
with academic medical centers are highly specialized, of-
ten with advanced training in surgical oncology, colorectal
and liver surgery, and chemotherapy specific to colon can-
cer. To our knowledge, at least one study to date has
shown an association between receipt of treatment by a
specialized surgeon and improved overall survival in
patients with colorectal cancer.28 Treatment by a special-
ized medical oncologist with expertise in colon cancer and
the ability to appropriately select those treatment options
most likely to confer clinical benefit could also contribute
to improved outcomes.
The multidisciplinary nature of academic settings
may also contribute to the difference in outcomes noted
in the current study. Academic medical centers provide a
range of cancer care specialists, and are more likely to pro-
vide primary, preventive, and supportive care services to
patients with cancer.29 This is particularly important in
the care of elderly patients with cancer, who often have
multiple comorbid conditions in addition to cancer.30
The availability of consulting physicians in an academic
setting may help to meet the complete health needs of
patients with colon cancer and may contribute to the
reduced risk of all-cause mortality observed in the current
study.
In addition, the undertreatment of elderly patients
with colorectal cancer has been well described in the litera-
ture.31,32 Providers at academic medical centers may have
more experience treating elderly patients with colon can-
cer and a greater level of comfort offering and managing
therapies that prolong overall survival. Although elderly
patients are significantly underrepresented in clinical trial
accrual in general,33,34 those treated at academic medical
centers have greater access to clinical trials than those
patients treated at nonacademic medical centers, and this
may also contribute, in small part, to the difference in
overall survival.
There are several limitations to the current study.
First, patients were assigned to the hospital at which they
were likely to have received their cancer care using the pri-
mary medical oncologist as an intermediary. It was not
possible to assign all patients to a treating hospital using
this method, and some patients may have been incorrectly
assigned. Second, there may be unmeasured differences
between patients with colon cancer who receive care at
academic medical centers and those who receive care at
nonacademic medical centers. Perhaps these patient dif-
ferences, rather than hospital academic status, are associ-
ated with the observed effects on outcomes. However,
when we adjusted for extensive patient-level factors, the
differences associated with hospital academic status per-
sisted. Nevertheless, the current analysis did not reveal the
causal mechanisms underlying this difference; hospital
academic status could be a proxy for some other causative
factor. Third, we excluded out-of-pocket costs to patients
in our calculation of overall cost to evaluate costs from the
payer’s (ie, Medicare) perspective. Because all patients in
the current study cohort were covered under Medicare
fee-for-service, we do not expect that the inclusion of
those costs would have significantly changed the results of
the current study. Fourth, our cost analyses do not
account for patient censoring. Patients who live longer
receive more care and thus incur more costs; given the
improved overall survival of patients treated at academic
medical centers, costs at these centers may appear greater
than those at nonacademic centers. Fifth, consistent with
prior studies,35,36 we used a Cox proportional hazards
approach to model survival, which treats deaths due to
other causes as independent from deaths due to colon can-
cer. Sixth, SEER-Medicare does not collect data regarding
quality of life and therefore we could not include this im-
portant patient outcome in our value estimates. Finally,
because the population of the current study was restricted
to patients aged >65 years, these findings cannot be gen-
eralized to younger patients with colon cancer. However,
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the average age of an individual at the time of a colon can-
cer diagnosis in the United States is 69 years, with the ma-
jority of patients diagnosed after age 65 years. Thus, it is
reasonable to study colon cancer in the Medicare
population.
Metastatic colon cancer is an ideal disease setting in
which to study site effects on the value of cancer care deliv-
ered and should serve as the model for further studies.
Unlike early-stage colon cancer, for which consensus
regarding the standard treatment approach and clear
guidelines for care exist, the treatment of metastatic colon
cancer is highly individualized with the potential for sub-
stantial variation depending on the care setting. Using ro-
bust population-based data, the results of the current
study indicated that overall survival was significantly
extended when elderly patients with metastatic colon can-
cer received cancer care from providers affiliated with an
academic medical center. Although the adjusted mean
cost of care was significantly greater for patients treated at
academic medical centers, it was only a small percentage
of patients who received very expensive care who contrib-
uted to this difference. Further research is needed to iden-
tify the drivers behind the differences in outcomes for
patients with metastatic colon cancer based on care set-
ting. Faced with high and rising health care costs, the
delivery of high-value health care that maximizes patient
outcomes while containing overall costs should be a
national priority.
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